Radiotherapy for Post-Chemotherapy Residual Mass in Advanced Seminoma: A Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography-Based Risk-adapted Approach.

[1]  C. Bokemeyer,et al.  Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  C. Fankhauser,et al.  Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  L. Giovanella,et al.  Diagnostic Performance of Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography in the Postchemotherapy Management of Patients with Seminoma: Systematic Review and Meta-Analysis , 2014, BioMed research international.

[4]  S. Rudman,et al.  Global incidence and outcome of testicular cancer , 2013, Clinical epidemiology.

[5]  A. Horwich,et al.  tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial , 2011 .

[6]  R. Motzer,et al.  Medical treatment of advanced testicular cancer. , 2008, JAMA.

[7]  J. Pinski,et al.  Postchemotherapy residual masses in advanced seminoma: current management and outcomes , 2005, Expert review of anticancer therapy.

[8]  C. Bokemeyer,et al.  2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Culine,et al.  Advanced seminoma—Treatment results and prognostic factors for survival after first‐line, cisplatin‐based chemotherapy and for patients with recurrent disease , 2003, Cancer.

[10]  B. Leibovich,et al.  Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity? , 2003, The Journal of urology.

[11]  P. Biron,et al.  Management of post-chemotherapy residual masses in advanced seminoma. , 2002, The Journal of urology.

[12]  Ong,et al.  The management of residual masses after chemotherapy in metastatic seminoma , 1999, BJU international.

[13]  A. Horwich,et al.  Radiotherapy after chemotherapy for metastatic seminoma--a diminishing role. MRC Testicular Tumour Working Party. , 1997, European journal of cancer.

[14]  R. Motzer,et al.  Surgery for a post-chemotherapy residual mass in seminoma. , 1997, The Journal of urology.

[15]  P. Wilkinson,et al.  International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Mazumdar,et al.  Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Williams,et al.  Simple nontoxic treatment of advanced metastatic seminoma with carboplatin. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Horwich,et al.  Advanced seminoma: treatment with cis-platinum-based combination chemotherapy or carboplatin (JM8). , 1985, British Journal of Cancer.

[19]  W. Brenner,et al.  The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma. , 2008, The Journal of urology.

[20]  J. Droz.  [Classification of germ cell tumors of the testis]. , 2007, La Revue du praticien.